Wealthfront Advisers LLC Makes New Investment in COMPASS Pathways plc (NASDAQ:CMPS)

Wealthfront Advisers LLC purchased a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 11,250 shares of the company’s stock, valued at approximately $43,000.

Several other institutional investors have also recently made changes to their positions in CMPS. Propel Bio Management LLC acquired a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $504,000. Acuta Capital Partners LLC acquired a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $2,435,000. Walleye Capital LLC acquired a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $2,126,000. Sio Capital Management LLC increased its position in shares of COMPASS Pathways by 211.7% during the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after purchasing an additional 621,222 shares during the last quarter. Finally, Polar Asset Management Partners Inc. increased its position in shares of COMPASS Pathways by 83.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after purchasing an additional 258,000 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on CMPS shares. Stifel Nicolaus started coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, Canaccord Genuity Group reduced their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Stock Performance

CMPS opened at $3.22 on Wednesday. The business has a fifty day simple moving average of $3.95 and a 200 day simple moving average of $4.92. The company has a market capitalization of $298.41 million, a PE ratio of -1.46 and a beta of 2.29. COMPASS Pathways plc has a 1 year low of $3.17 and a 1 year high of $10.31. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Research analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.